Impacts of treatment lines and initiation timing of erlotinib for advanced non-small cell lung cancer
T Aoki, S Igawa, N Furuya, M Katagiri… - Anticancer …, 2012 - ar.iiarjournals.org
Aim: This study aimed to analyze whether or not the efficacy and safety of erlotinib are
influenced by differences among treatment lines and initiation timing in advanced non-small …
influenced by differences among treatment lines and initiation timing in advanced non-small …
[HTML][HTML] Second-and further-line therapy with erlotinib in patients with advanced non-small-cell lung cancer in daily clinical practice
J Krainhöfer, M Walther, M Steinert… - BioMed Research …, 2014 - hindawi.com
Introduction. The aim of this retrospective study was to examine effect of erlotinib in patients
with advanced non-small cell lung cancer (NSCLC) in second-line and further therapy in …
with advanced non-small cell lung cancer (NSCLC) in second-line and further therapy in …
[PDF][PDF] Efficacy and safety of erlotinib versus chemotherapy in second-line advanced non-small-cell lung cancer (NSCLC) with poor prognosis: The phase III TITAN …
T Ciuleanu, L Stelmakh, S Cicenas… - Chemotherapy (n …, 2011 - academia.edu
Background: Erlotinib, docetaxel and pemetrexed are all approved in the second-line setting
for patients with advanced NSCLC who progress following first-line platinum doublet …
for patients with advanced NSCLC who progress following first-line platinum doublet …
Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes …
P Neumair, L Joos, R Warschkow, A Dutly, S Ess, F Hitz… - Lung Cancer, 2016 - Elsevier
Objectives Controversy exists about the integration of erlotinib in patients with EGFR
wildtype, advanced NSCLC. Materials and methods We included patients with advanced …
wildtype, advanced NSCLC. Materials and methods We included patients with advanced …
Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non–small-cell lung cancer
Purpose This study investigated whether sequential administration of erlotinib and
chemotherapy improves clinical outcomes versus chemotherapy alone in unselected …
chemotherapy improves clinical outcomes versus chemotherapy alone in unselected …
Erlotinib monotherapy in patients with advanced non-small cell lung cancer: an effective approach with low toxicity
A Ardavanis, S Koumna, I Fragos, S Malliou… - Anticancer …, 2008 - ar.iiarjournals.org
Background: Treatment of non-small cell lung cancer (NSCLC) with tyrosine kinase
inhibitors (TKIs) of epidermal growth factor receptor (EGFR) and particularly erlotinib …
inhibitors (TKIs) of epidermal growth factor receptor (EGFR) and particularly erlotinib …
Erlotinib for frontline treatment of advanced non–small cell lung cancer: a phase II study
G Giaccone, M Gallegos Ruiz, T Le Chevalier… - Clinical Cancer …, 2006 - AACR
Purpose: Erlotinib has proven activity in pretreated patients with advanced non–small cell
lung cancer (NSCLC). We evaluated erlotinib in the frontline treatment of advanced NSCLC …
lung cancer (NSCLC). We evaluated erlotinib in the frontline treatment of advanced NSCLC …
A phase II study of first-line erlotinib in patients (pts) with stage IIIB/IV non-small-cell lung cancer (NSCLC) including dose escalation to toxicity in current and former …
8111 Background: Skin rash has been associated with increased activity of erlotinib in
retrospective analyses and plasma levels of erlotinib are lower in current vs former or non …
retrospective analyses and plasma levels of erlotinib are lower in current vs former or non …
FAST-ACT: A phase II randomized double-blind trial of sequential erlotinib and chemotherapy as first-line treatment in patients (pts) with stage IIIB/IV non-small cell …
8031 Background: Concurrent administration of EGFR TKIs and chemotherapy in 1st line
failed to improve survival. Preclinical data suggested potential antagonism due to TKI …
failed to improve survival. Preclinical data suggested potential antagonism due to TKI …
Final survival and safety results from a multicenter, open‐label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer
DR Spigel, M Lin, V O'Neill… - … International Journal of …, 2008 - Wiley Online Library
BACKGROUND. Erlotinib is an orally available, reversible inhibitor of epidermal growth
factor receptor (EGFR) with a proven survival advantage for patients with locally advanced …
factor receptor (EGFR) with a proven survival advantage for patients with locally advanced …